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and assessments of symptom severity (as assessed with the PANSS) in a population-based sample 
of FEP patients (77 with schizophreniform psychosis and 53 with affective psychoses) and 191 
neighboring healthy controls. Results: There was no difference in the proportion of Met allele 
cognitive test scores in either of the psychosis groups. A decreased severity of negative symptoms 
et al
subgroup with affective psychoses (p < 0.01, ANOVA). Conclusions: These results suggest that, 
functioning but may modulate the severity of negative symptoms.
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Introduction
Brain derived neurotrophic factor (BDNF) is a neurotrophin 
of key relevance in the central nervous system, being crucial 
for neurodevelopment, the formation of neural networks and 
neuronal plasticity. A functional polymorphism (rs6265) in the 
human BDNF gene producing an amino acid substitution of 
valine to methionine at codon 66 (Val66Met) has been shown 
having as consequence an impaired secretion of BDNF.1 Some 
studies suggest that the presence of the Met allele in healthy 
2,3 although this 
4
Several authors have proposed that BDNF expression 
disorders.5-11 An association between the Met BDNF allele 
and impaired cognitive performance has been found in in-
dividuals with mood disorders12 or schizophrenia,13 although 
there has been no clear demonstration of an excess of Met 
BDNF allele carriers in patients with those mental disorders 
relative to healthy controls.10,14 On the other hand, some 
studies have reported an over-transmission of the Val allele 
to affected offspring both in schizophrenia15 and bipolar 
disorder patients,16 suggesting that the presence of the Met 
allele may have a protective effect for individuals at risk for 
those psychiatric disorders. Furthermore, Chang et al.17 have 
shown that the Met allele may be associated with reduced 
severity of negative symptoms of schizophrenia. Taken to-
mood disorders.10
assessed with morphometric magnetic resonance imaging18 and 
cognitive impairment19,20 in a population-based sample of pa-
environmentally-matched healthy controls, and demonstrated 
-
21 In the present study, 
cognitive performance and clinical symptomatology in a larger 
group of FEP sample, which substantially overlapped with the 
FEP sample investigated in our previous studies. As we aimed 
to investigate the relationship between the Val66Met BDNF 
polymorphism and clinical/cognitive features of psychosis, it 
was of critical importance to assess patients with a recent 
of continued medication use and effects of illness chronicity 
on the expression of symptoms.
Methods
The psychosis group (age 18-64) was drawn from a sample 
study on the incidence of psychotic disorders in a circum-
scribed area of São Paulo, Brazil.22
with the Structured Interview for DSM-IV,23 the Positive and 
Negative Syndrome Scale (PANSS),24 the Alcohol Use Disorders 
25 the South Westminster Questionnaire26 
and Annett’s handedness questionnaire.27
In order to obtain a population-based psychosis-free 
sample of controls, next-door neighbors were contacted and 
screened to exclude the presence of psychotic symptoms us-
ing the Psychosis Screening Questionnaire.28 The additional 
exclusion criteria outlined above also applied to the control 
group. Further details on the selection and recruitment of 
19,22
A short neuropsychological battery was applied both 
to FEP patients and controls,19 including the forward and 
backward digit span tests from the Wechsler Memory Scale 
– Third Edition,29 and the Controlled Oral Word Association 
Test30 to measure verbal fluency. The G196A/Val66Met 
(rs 6265) polymorphism in BDNF gene was genotyped accord-
ing to the methods of Egan et al.3
Between-group comparisons were conducted using 
Pearson’s chi-square test for categorical variables and uni-
variate ANOVAs for continuous variables using the Statistical 
-
cance adopted was p < 0.05.
The study was approved by local ethics committees, and 
Results
From the original sample of 200 FEP patients and 400 controls 
enrolled in the epidemiological study (Menezes et al.27), the 
total number of individuals who underwent BDNF genotyping 
was 130 FEP patients (77 with schizophreniform psychosis and 
53 with affective psychoses) and 191 controls. The remaining 
genetics arm of the investigation, or because they refused to 
participate. The FEP group recruited for the present study 
was representative of the overall FEP sample, as there were 
no statistical differences between the FEP patients who un-
derwent BDNF genotyping and those who did not in regard to 
gender distribution (p = 0.17), handedness (p = 0.41), school-
ing (p = 0.10), alcohol (p = 0.37) and/or drug abuse (p = 0.51), 
except for a marginal difference in age (p = 0.02, with mean 
ages of genotyped and non-genotyped cases equal to 30.98 and 
34.76, respectively). For the purposes of the following analyses, 
Met/Met homozygous and Val/Met heterozygous individuals 
were grouped together as Met carriers.
Table 1 shows the demographic, clinical and genotype 
-
trol groups, divided by their BDNF Val66Met polymorphism 
Weinberg equilibrium in either of the two groups. There was 
between FEP patients and controls, or between the differ-
ent subtypes of psychosis (schizophreniform versus affective 
psychoses) (Table 1). No interaction was found between 
genotypes and age, handedness, alcohol abuse, drug abuse, 
schooling, mean age of disease onset, use of benzodiazepines 
or use of antipsychotics either for the whole group or when 
the healthy controls and patients were examined separately, 
except for a higher presence of Met carriers among healthy 
cognitive and clinical assessment in any group (data not 
in the prevalence of alcohol and drug abuse between FEP and 
in regard to sex, age and handedness (Table 1).
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Table 2 shows the relationship between BDNF Val66Met 
genotype and cognitive variables in FEP patients and controls. 
No genotype x diagnosis interaction was found on cognitive 
performance. When comparisons were performed using 
the separate categories for schizophreniform and affective 
the three cognitive tests between the subgroups divided 
according to the Val66Met genotype (Table 2).
Table 3 summarizes the pattern of relationship between 
psychopathological assessments in FEP patients and BDNF 
Val66met genotype. FEP patients who had the Met allele 
showed reduced negative symptomatology. The subgroup 
analyses conducted using the separate categories for 
schizophreniform and affective psychoses indicated that such 
difference was evident for the mood disorder subgroup but 
not for the schizophreniform psychosis subgroup (Table 3). 
Discussion
the BDNF Val66Met polymorphism (rs 6265) either with the 
of schizophreniform and affective psychoses. These results 
similar methods and included samples of size similar to ours 
or larger.14,31
Table 1 Demographic features in relation to diagnosis, BDNF genotype and their interaction
Mean (SD)
Diagnostic X Genotype interaction




with FEP  














N = 5 p value
BDNF VAL66MET genotype
VAL/VAL (%)






NA NA NA NA
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2 tests, while differences in continuous variables were investigated using ANOVA. aNumber 
of years of formal education.
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Also, even though previous studies have suggested ge-
32,33 it was 
found no interaction between BDNF genotype and general 
cognitive performance in FEP. These results are in contrast 
related structural brain abnormalities in a FEP sample that 
very substantially overlapped with the FEP group studied 
herein.18,21
studies argue against a view that structural brain abnormali-
It is important to note that, due to the need to devise 
a neuropsychological battery easily applicable in the con-
text of a large epidemiological study, it was only tested a 
limited number of cognitive functions in the current study. 
Perhaps the inclusion of other cognitive tests could reveal a 
Table 2A 
Val66Met genotyping 
Cognitive Mean Scores (SD)
Main effect of diagnosis




















N = 5 p value
Verbal Fluency 25.76(10.65) 23.19(10.61) 0.03 24.92(10.58) 28.20 (10.59) 0.06 22.51(10.79) 24.62(10.20) 0.29
Digit span forward 5.32 (2.43) 4.49 (2.00) 0.001 5.18(2.26) 5.73(2.87) 0.17 4.41 (1.97) 4.67 (2.07) 0.49
Digit span backward 4.89(2.04) 3.95(2.01) 0.001 4.77(2.01) 5.22(2.11) 0.18 4.02(2) 3.81(2.05) 0.57
Table 2B
according to BDNF Val66Met genotyping
Cognitive Mean Scores (SD)
Subdiagnosis of FEP X Genotype interaction




















N = 2 p value
Digit span forward 4.56(2.16) 4.40(1.75) 0.65 4.60(2.18) 4.45(2.15) 0.79 4.09(1.52) 4.90(2.00) 0.10
Digit span backward 3.94(2.91) 3.98(1.73) 0.90 4.15(2.11) 3.41(2.34) 0.18 3.82(1.81) 4.25(1.61) 0.39
22.64(9.77) 24.00(11.78) 0.47 22.42(9.26) 23.18(11.13) 0.76 22.67(13.10) 26.20(9.09) 0.29
Table 3
Val66Met genotyping
PANSS Mean Scores (SD)
Subtype of FEP X Genotype interaction
















N = 2 p value
Total symptom scores 46.13 (13.59) 42.66 (10.52) 0.12 46.87 (13.78) 44.27 (13.26) 0.45 44.97 (11.8) 38.85 (6.63) 0.04
Positive symptom scores 10.56 (4.13) 10.21 (4.73) 0.65 10.40 (4.02) 10.95 (4.44) 0.59 10.67 (5.25) 9.45 (3.72) 0.37
Negative symptom scores 12.65 (5.62) 10.23 (4.10) 0.01 13.16 (5.96) 11.36 (4.57) 0.20 11.33 (4.65) 8.40 (1.98) 0.01
General symptom scores 22.92 (6.48) 22.23 (4.46) 0.50 23.31 (6.90) 21.95 (5.34) 0.41 22.97 (4.81) 21 (3.627) 0.12
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Consistent with this possibility, previous investigations of 
patients with schizophrenia have suggested that BDNF poly-
their visuospatial13 and attentional performance,34 but not on 
other cognitive abilities. Also, regardless of diagnostic status, 
such investigations13 have suggested that the BDNF Met vari-
episodic memory performance, which was not evaluated in 
the current study. Finally, one has also to consider that other 
evaluated in our FEP sample than the BDNF gene evaluated 
in the current study.
-
creased severity of negative symptoms and the presence of 
the Met al -
17 When we carried out separate 
analyses for diagnostic subgroups in the present study, the 
severity of negative symptoms was reduced in Met carriers 
variant and negative symptom scores in the sample of af-
Negative symptoms in affective psychoses may not remain 
stable over time, and do not persist during the post-acute 
phase of such disorders.35,36 However, negative symptoms 
do occur in the acute phase of affective psychoses, and our 
results suggest that BDNF expression may play an important 
role on the emergence and severity of these symptoms in such 
patients. The presence of the Met66 variant is known to de-
crease BDNF expression,3 and this could lead to a decrement 
in negative symptom severity by reducing the expression of 
the D3R.37,38 This dopamine receptor subtype has been found 
to be reduced in patients presenting psychotic episodes, but 
it is conversely over-expressed in the presence of negative 
symptoms.39 The presence of a Met allele might modify the 
synaptic strength of pathways implicated in the emergence 
of negative symptoms in affective FEP.
higher prevalence of Met carriers among healthy women. 
Gender differences in genotype distribution have been 
reported before.40 However, in our study, separate analyses 
-
rameter on cognitive and clinical ratings in any of the groups.
A number of limitations must be taken into account 
when interpreting our results. First and foremost, the size 
of our sample is relatively modest, thus increasing the risk 
of both type I and II errors. Second, even though statisti-
cal analyses showed that the Met allele was independently 
related to a decreased severity of negative symptoms, the 
lead to motor side effects that mimic negative symptoms. 
Third, we have evaluated psychopathology and cognitive 
performance at a single point in time. Therefore, the effect 
of BDNF genotype on clinical symptoms may be transient. 
Fourth, we were not able to collect data on serum BDNF 
levels,11,34 and this prevented us from investigating correla-
tions between plasma BDNF levels and cognitive symptom; 
this would have added relevant information on the interplay 
between activity-dependent BDNF secretion, genotype and 
clinical features of psychosis. 
gene Val66Met polymorphism does not have a pervasive 
severity of negative symptoms. Further longitudinal studies 
of FEP involving more comprehensive cognitive batteries 
and serial evaluations of clinical symptoms in larger samples 
are warranted, as well as studies using probes to evaluate 
the interplay between BDNF expression and BDNF-regulated 
neurotransmitter systems that are relevant to the emergence 
of psychosis symptoms, such as the dopaminergic system.
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Resumo
Objetivo
(BDNF) no desempenho cognitivo e na sintomatologia clínica durante o primeiro episódio psicótico 
(PEP). Métodos
(conforme avaliado pela Positive and Negative Syndrome Scale [PANSS]) em uma amostra de 
pacientes com PEP de base populacional (77 com psicose esquizofreniforme e 53 com psicose 
afetiva) e 191 vizinhos controle saudáveis. Resultados: Não houve diferença na proporção de 
(p < 0,01, ANOVA). Conclusões
modular a gravidade dos sintomas negativos.
DESCRITORES:
Escala das Síndromes 
Positivas e Negativas; 
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Tabela 1
Média (DP)
Efeito principal do  diagnóstico





com PEP  














N = 5 valor de p 
Genótipo VAL66MET do 
BDNF
VAL/VAL (%)





0,19 NA NA NA NA














































Menos de 8 anos (%)























































































2, enquanto as diferenças em variáveis contínuas foram investigadas usando o 
ANOVA. aNúmero de anos de educação formal; DP: desvio padrão; PEP: primeiro episódio psicótico; NA: não aplicável; VAL: valina; MET: metionina.
presença maior de portadores Met entre mulheres saudáveis 
as avaliações cognitiva e clínica em qualquer um dos grupos (os 
dados não são mostrados). Não foram encontradas diferenças 
(Tabela 1).
A Tabela 2 mostra a relação entre o genótipo Val66Met 
do BDNF e as variáveis cognitivas em pacientes PEP e no 
grupo controle. Não foi encontrada alteração na relação 
genótipo x diagnóstico no desempenho cognitivo. Quando 
foram feitas comparações usando categorias separadas para 
as psicoses esquizofeniforme e afetiva, novamente não 
-
vos entre os subgrupos divididos de acordo com o genótipo 
Val66Met (Tabela 2).
A Tabela 3 resume o padrão da relação entre as avaliações 
psicopatológicas em pacientes PEP e o genótipo Val66met do 
BDNF. Os pacientes com PEP que apresentavam o alelo Met 
mostraram sintomatologia negativa reduzida. As análises de 
subgrupo conduzidas que usavam as categorias separadas 
para as psicoses esquizofreniformes e afetivas indicaram que 
S229
Tabela 2A Comparação das pontuações dos testes cognitivos de pacientes com primeiro episódio psicótico e pacientes 
Pontuação cognitiva média (DP)
Efeito principal do diagnóstico





com PEP  














N = 5 valor de p
Fluência verbal 25,76(10,65) 23,19(10,61) 0,03 24,92(10,58) 28,20 (10,59) 0,06 22,51(10,79) 24,62(10,20) 0,29
Repetição de dígito na 
ordem direta 5,32 (2,43) 4,49 (2,00) 0,001 5,18(2,26) 5,73(2,87) 0,17 4,41 (1,97) 4,67 (2,07) 0,49
Repetição de dígito na 
ordem inversa 4,89(2,04) 3,95(2,01) 0,001 4,77(2,01) 5,22(2,11) 0,18 4,02(2) 3,81(2,05) 0,57
Tabela 2B Comparação das pontuações dos testes cognitivos de subcategorias diagnósticas do primeiro episódio psicótico 
Pontuação cognitiva média (DP)
Subdiagnóstico de PEP  X  Interação genotípica



















N = 2 valor de p
Repetição de dígito na 
ordem direta
4,56(2,16) 4,40(1,75) 0,65 4,60(2,18) 4,45(2,15) 0,79 4,09(1,52) 4,90(2,00) 0,10
Repetição de dígito na 
ordem inversa
3,94(2,91) 3,98(1,73) 0,90 4,15(2,11) 3,41(2,34) 0,18 3,82(1,81) 4,25(1,61) 0,39
Fluência verbal 22,64(9,77) 24,00(11,78) 0,47 22,42(9,26) 23,18(11,13) 0,76 22,67(13,10) 26,20(9,09) 0,29
Diferenças de grupo foram investigadas usando o ANOVA, DP: desvio padrão; PEP: primeiro episódio psicótico; NA: não aplicável; VAL: valina; MET: 
metionina.
tal diferença era evidente para o subgrupo com transtorno 
de humor, mas não para o subgrupo com psicose esquizofre-
niforme (Tabela 3). 
Discussão
No presente estudo, não foi encontrada uma associação 
 do BDNF 
(rs 6265) tanto com o diagnóstico geral de PEP quanto com 
-
freniforme e afetiva. Esses resultados são consistentes com 
as descobertas de estudos anteriores que usaram métodos 
similares e incluíram amostras de tamanho semelhante ou 
maior do que a nossa.14,31
Além disso, embora estudos anteriores tenham sugeri-
PEP,32,33 não encontramos interação entre o genótipo do 
BDNF e o desempenho cognitivo geral em PEP. Esses resul-
tados contrastam com nossas descobertas anteriores acerca 
substancialmente ao grupo PEP aqui estudado.18,21 Tomados 
argumentam contra uma visão de que as anormalidades 
do gene do BDNF. 
no contexto de um amplo estudo epidemiológico, foi testado 
apenas um número limitado de funções cognitivas no presente 
estudo. Talvez a inclusão de outros testes cognitivos revelasse 
cognição em PEP. Consistentes com essa possibilidade, inves-
tigações anteriores com pacientes esquizofrênicos sugeriram 
espacial13 e atentivo,34 mas não em outras habilidades cog-
nitivas. Ainda, independentemente do status do diagnóstico, 
tais investigações13 sugeriram que o variante Met do BDNF 
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Tabela 3 Comparação das pontuações da PANSS das subcategorias diagnósticas do primeiro episódio psicótico divididas 
Pontuação média de PANSS (DP)
Subtipo de PEP X Interação genotípica















N = 2 valor de p
Pontuação total de 
sintomas 46,13 (13,59) 42,66 (10,52) 0,12 46,87 (13,78) 44,27 (13,26) 0,45 44,97 (11,8) 38,85 (6,63) 0,04
Pontuação de sintomas 
positivos 10,56 (4,13) 10,21 (4,73) 0,65 10,40 (4,02) 10,95 (4,44) 0,59 10,67 (5,25) 9,45 (3,72) 0,37
Pontuação de sintomas 
negativos 12,65 (5,62) 10,23 (4,10) 0,01 13,16 (5,96) 11,36 (4,57) 0,20 11,33 (4,65) 8,40 (1,98) 0,01
Pontuação de sintomas 
gerais 22,92 (6,48) 22,23 (4,46) 0,50 23,31 (6,90) 21,95 (5,34) 0,41 22,97 (4,81) 21 (3,627) 0,12
Diferenças de grupo foram investigadas usando o ANOVA, DP: desvio padrão; PEP: primeiro episódio psicótico; NA: não aplicável; VAL: valina; MET: metionina.
episódica verbal relacionada com o lobo temporal medial, 
maior sobre os índices cognitivos avaliados em nossa amostra 
PEP do que o gene do BDNF avaliado neste estudo.
-
cionados, nossas análises revelaram uma associação sig-
 dos sintomas 
Estudos anteriores apresentaram uma relação similar es-
17 Quando 
conduzimos análises separadas para subgrupos diagnósticos 
no presente estudo, a gravidade dos sintomas negativos foi 
reduzida nos portadores de Met com esquizofrenia, mas 
outro lado, a relação entre a variante Met66 e a pontuação 
negativos em psicoses afetivas podem não se manter 
constantes ao longo do tempo e não persistir depois da 
fase aguda de tais transtornos.35,36 No entanto, os sinto-
mas negativos não ocorrem na fase aguda das psicoses 
afetivas e os resultados encontrados aqui sugerem que a 
expressão do BDNF pode ter um papel importante sobre o 
aparecimento e a severidade desses sintomas em tais pa-
cientes. Sabe-se que a presença da variante Met66 diminui 
a expressão do BDNF3 e isso poderia levar ao decréscimo 
da severidade do sintoma negativo ao reduzir a expressão 
de D3R.37,38 Observou-se que esse subtipo de receptor de 
dopamina é reduzido em pacientes que apresentam episó-
dios psicóticos, mas é inversamente elevado na presença 
de sintomas negativos.39 A presença de um alelo Met pode 
no aparecimento de sintomas negativos em PEP afetivo.
Outro achado importante do presente estudo é a preva-
lência maior de portadores de Met entre mulheres saudáveis. 
Já foram relatadas anteriormente diferenças de gênero 
quanto à distribuição genotípica.40 No entanto, em nosso 
cognitivas e clínicas em cada um dos grupos.
Uma série de limitações deve ser levada em consideração 
ao se interpretar os resultados. Em primeiro lugar, o tamanho 
de nossa amostra é relativamente modesto, o que aumenta 
o risco dos erros do tipo I e II. Em segundo lugar, embora as 
análises estatísticas tenham mostrado que o alelo Met es-
tava independentemente relacionado a uma diminuição da 
severidade dos sintomas negativos, a maioria dos pacientes 
recebeu antipsicóticos, que podem levar a efeitos colaterais 
motores que imitam os sintomas negativos. Em terceiro lugar, 
avaliamos a psicopatologia e o desempenho cognitivo em um 
único momento ao longo do tempo. Dessa forma, o efeito do 
genótipo do BDNF em sintomas clínicos pode ser transitório. 
Em quarto lugar, não foi possível coletar dados em níveis 
séricos de BDNF,11,34 privando-nos de investigar correlações 
entre os níveis plasmáticos de BDNF e o sintoma cognitivo. 
Tal fato contribuiria com informações relevantes quanto à 
interação entre a secreção dependente da atividade de BDNF, 
o genótipo e os recursos clínicos de psicose.
Finalmente, nossos achados sugerem que, em PEP, o 
-
dular a severidade dos sintomas negativos. Novos estudos 
longitudinais de PEP envolvendo baterias cognitivas mais 
abrangentes e avaliações seriadas de sintomas clínicos em 
amostras mais amplas são necessários, bem como estudos que 
usam sondagens para avaliar a interação entre a expressão 
de BDNF e os sistemas neurotransmissores regulados por 
BDNF que são relevantes para o aparecimento dos sintomas 
de psicose, tais como o sistema dopaminérgico.     
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